NCT03986593

Cryoablation of Bone Metastases From Endocrine Tumors

Cone-beam Computed Tomography Guided Percutaneous Cryoablation of Bone Metastases From Endocrine Tumors

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Instituto do Cancer do Estado de São Paulo · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the clinical response and safety of cone beam computed-tomography guided percutaneous cryoablation in bone metastases from thyroid, adrenal and neuroendocrine tumors in 30 patients.

Detailed description

Thyroid neoplasms, as well as adrenal and neuroendocrine tumors have the potential to metastasize to bone. About 3% of patients with well-differentiated thyroid carcinomas develop secondary bone lesions, while adrenal and neuroendocrine tumors have 10% and 13% bone metastases rates, respectively. Spinal metastases are associated to a worst prognosis. The progressive systemic disease, the post-operative complications, and the pre-operative neurologic impairment were associated to a worst global survival rate in the thyroid cancer. Additionally, extensive spinal instrumentation of metastatic thyroid carcinoma was associated to greater complication rates. Interventional radiology offers promising techniques for the minimally invasive approach of bone metastases. Image-guided percutaneous radiofrequency ablation and cryoablation techniques have been studied in clinical trials and are considered effective options in pain palliation of patients with bone metastatic disease. These techniques may be associated with conventional treatment, as well as radiation therapy and percutaneous embolization, avoiding major surgical interventions and its complications.

Conditions

• Neoplasm Metastasis
• Thyroid Neoplasm
• Pheochromocytoma
• Adrenal Neoplasm
• Neuroendocrine Tumors
• Bone Metastases

Interventions

Type	Name	Description
DEVICE	cryoablation	cryoablation of bone metastases by cone beam-CT image-guidance

Timeline

• Start date: 2019-09-26
• Primary completion: 2022-10-15
• Completion: 2023-05-29
• First posted: 2019-06-14
• Last updated: 2023-07-05

Locations

1 site across 1 country: Brazil

Regulatory

• FDA-regulated device study